SMAD4 and TGFβ are architects of inverse genetic programs during fate-determination of antiviral CTLs

  1. Karthik Chandiran
  2. Jenny E Suarez-Ramirez
  3. Yinghong Hu
  4. Evan R Jellison
  5. Zenep Ugur
  6. Jun-Siong Low
  7. Bryan McDonald
  8. Susan M M Kaech
  9. Linda S Cauley  Is a corresponding author
  1. University of Connecticut Health Center, United States
  2. Emory University, United States
  3. Yale University, Switzerland
  4. Salk Institute for Biological Studies, United States

Peer review process

This article was accepted for publication via eLife's original publishing model. eLife publishes the authors' accepted manuscript as a PDF only version before the full Version of Record is ready for publication. Peer reviews are published along with the Version of Record.

History

  1. Version of Record updated
  2. Version of Record published
  3. Accepted Manuscript updated
  4. Accepted Manuscript published
  5. Accepted
  6. Received
  7. Preprint posted

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Karthik Chandiran
  2. Jenny E Suarez-Ramirez
  3. Yinghong Hu
  4. Evan R Jellison
  5. Zenep Ugur
  6. Jun-Siong Low
  7. Bryan McDonald
  8. Susan M M Kaech
  9. Linda S Cauley
(2022)
SMAD4 and TGFβ are architects of inverse genetic programs during fate-determination of antiviral CTLs
eLife 11:e76457.
https://doi.org/10.7554/eLife.76457

Share this article

https://doi.org/10.7554/eLife.76457